MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on July 20, 2006; DOI: 10.1124/mol.106.027318


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.106.027318v1
70/4/1454    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Xiao, Y.
Right arrow Articles by Kellar, K. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Xiao, Y.
Right arrow Articles by Kellar, K. J.


Received for publication May 31, 2006.
Revised July 14, 2006.
Accepted for publication July 14, 2006.

Sazetidine-A, a Novel Ligand that Desensitizes {alpha}4 {beta}2 Nicotinic Acetylcholine Receptors Without Activating Them

Yingxian Xiao 1, Hong Fan 2, John L. Musachio 2, Sheela K. Chellappan 3, Zhi-Liang Wei 3, Alan P. Kozikowski 3, Kenneth J. Kellar 4*

1 Georgetown University 2 Johns Hopkins U. 3 U. Illinois 4 Georgetown University School of Medicine

* Address correspondence to: E-mail: kellark{at}georgetown.edu

Abstract

Neuronal nicotinic acetylcholine receptors (nAChRs) are ligand-gated ion channels found throughout the central and peripheral nervous systems. They are crucial to normal physiology and have been clearly implicated in addiction to nicotine. In addition to nicotine addiction, they are possible therapeutic targets in a wide range of pathological conditions, including cognitive disorders, Parkinson's disease and neuropathic pain. Nicotinic ligands are usually classified as agonists (or partial agonists), competitive antagonists or noncompetitive antagonists. Sazetidine-A is a new nicotinic ligand that shows a different pharmacological profile from any of these known classes of ligands. Sazetidine-A competes with very high binding affinity (Ki {approx} 0.5 nM) and selectivity for the {alpha}4{beta}2 nAChR subtype (Ki ratio {alpha}3{beta}4/{alpha}4{beta}2 ~ 24,000). Despite its high affinity, sazetidine-A does not activate nAChR channel function; nor does it prevent channel activation when it is applied simultaneously with nicotine. However, when it is preincubated for 10 minutes with the receptors, it potently blocks nicotine-stimulated {alpha}4{beta}2 nAChR function (IC50 {approx} 30 nM). The action of sazetidine-A may be explained by its very low affinity for the resting conformation of the {alpha}4{beta}2 nAChRs, and its very high affinity for the desensitized state of the receptor. We propose that sazetidine-A is a "silent desensitizer" of nAChRs, meaning it desensitizes the receptor without first activating it. Furthermore, comparison of the effects of sazetidine-A and nicotine at {alpha}4{beta}2 nAChRs suggest that the predominant effects of nicotine and other nicotinic agonists are related to desensitization of the receptors and that sazetidine-A potently mimics these effects.


Key words: Nicotinic cholinergic, Receptor binding studies, Regulation - post-transcriptional, Drug tolerance/dependence


This article has been cited by other articles:


Home page
Mol. Pharmacol.Home page
R. Zwart, A. L. Carbone, M. Moroni, I. Bermudez, A. J. Mogg, E. A. Folly, L. M. Broad, A. C. Williams, D. Zhang, C. Ding, et al.
Sazetidine-A Is a Potent and Selective Agonist at Native and Recombinant {alpha}4{beta}2 Nicotinic Acetylcholine Receptors
Mol. Pharmacol., June 1, 2008; 73(6): 1838 - 1843.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics